SCHEMBL20852437

SCHEMBL20852437

CCC(=O)Nc1ccc(C#N)c(C(F)(F)F)c1

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.62
RORC P51449 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28647119 0.89 AR (0.61) ARRORC
SCHEMBL3289165 0.88 AR (0.58) ARRORC
SCHEMBL20113375 0.87 AR (0.59) ARRORC
SCHEMBL9369888 0.86 AR (0.60) AR
SCHEMBL1772715 0.86 AR (0.68) AR
SCHEMBL1773545 0.86 AR (0.62) AR
SCHEMBL19695360 0.85 AR (0.62) AR
SCHEMBL29504198 0.85 AR (0.62) AR
SCHEMBL3289077 0.85 AR (0.55) ARRORC
SCHEMBL202061 0.84 AR (0.52) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4110322-A1 SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF University of Tennessee Research Foundation (US) 2023-01-04 EP disclosed
WO-2019060809-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE CHANNEL THERAPEUTICS, INC. (US) 2019-03-28 WO disclosed